poisar

Stocks · News reference

Truist Securities Maintains Buy on Globus Medical, Lowers Price Target to $100

Jul 16, 2026, 4:04 PMBenzinga Newsdesk

Truist Securities analyst Richard Newitter maintains Globus Medical (NYSE:GMED) with a Buy and lowers the price target from $115 to $100.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

GMED
Source
benzinga
Observed
Jul 16, 2026, 4:04 PM
Checked
Jul 16, 2026, 4:04 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 3:31 PMNa

    Veeva Systems Q2 Earnings and Revenues Beat Estimates, Stock Up

    Veeva Systems (VEEV) reported Q2 fiscal 2027 adjusted EPS of $2.35, up 18.1% YoY and beating consensus by 5.9%, with revenues rising 17.6% to $928 million. The company raised its fiscal 2027 revenue guidance to $3.682-$3.687 billion and EPS to $9.21. Vault CRM momentum continued with over 180 customers live including five top 20 biopharmas, while the company advanced its AI strategy with Veeva Falcon.

    Read original at zacks-investment-research
    VEEVGMEDWSTCOO
  2. Aug 26, 2026, 9:57 PMNa

    Globus Medical Announces Acquisition of Higgs Boson Health to Transform Healthcare Experience Through AI-Driven Digital Solutions

    Globus Medical, Inc. announced the acquisition of Higgs Boson Health, a Durham, NC-based digital healthcare company incubated from Duke University. The acquisition aims to enhance Globus Medical's ecosystem by integrating AI-driven digital solutions and surgical intelligence capabilities to improve patient outcomes in musculoskeletal surgeries, with a goal of achieving 95% good outcomes at 10 years.

    Read original at globenewswire-inc
    GMED